Literature DB >> 10732967

Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane)trans(acetate)2Cl2].

S R Ali Khan1, S Huang, S Shamsuddin, S Inutsuka, K H Whitmire, Z H Siddik, A R Khokhar.   

Abstract

A series of new platinum(IV) complexes of the type [PtIV(DACH)trans(L)2Cl2] (where DACH = trans-1R,2R-diaminocyclohexane, and L = acetate, propionate, butyrate, valerate, hexanoate, or heptanoate) bearing the carboxylate groups in the axial positions have been synthesized and characterized by elemental analysis, IR, and 195Pt NMR spectroscopy. The crystal structure of the analogue [PtIV(DACH)trans(acetate)2Cl2] was determined by single crystal X-ray diffraction method. There were two crystallographically independent molecules, both of which lie on crystallographic two-fold axes. The bond lengths and bond angles of both the molecules were the same within the experimental error. The compound crystallizes in the monoclinic space group C2, with a = 11.180(2) A, b = 14.736(3) A, c = 10.644(2) A, beta = 112.38(3) degrees, Z = 4 and R = 0.0336, based upon a total of 1648 collected reflections. In this complex, the platinum had a slightly distorted octahedron geometry owing to the presence of a geometrically strained five-member ring. The two adjacent corners of the platinum plane were occupied by the two amino nitrogens of DACH, whereas the other two equatorial positions were occupied by two chloride ions. The remaining two axial positions were occupied by the oxygens of acetate ligands. The DACH ring was in a chair configuration. An intricate network of intermolecular hydrogen bonds held the crystal lattice together. These analogues were evaluated in vitro and demonstrated cytotoxic activity against the human ovarian 2008 tumor cell line (IC50 = 0.001-0.06 microM). Structure-activity study revealed that activity was highest for the analogue where L = butyrate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732967     DOI: 10.1016/s0968-0896(99)00313-2

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling.

Authors:  Paola Gramatica; Ester Papa; Mara Luini; Elena Monti; Marzia B Gariboldi; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-06-06       Impact factor: 3.358

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs.

Authors:  Timothy C Johnstone; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-07-16       Impact factor: 5.165

4.  Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.

Authors:  Amarasooriya M D S Jayawardhana; Yao-Rong Zheng
Journal:  Dalton Trans       Date:  2022-02-01       Impact factor: 4.390

5.  Octa-n-butyl-1κC,2κC,3κ,4κC-bis-(μ-2,3-dibromo-propionato)-1:2κO:O',3:4κO:O'-bis-(2,3-dibromo-propionato)-1κO,3κO-di-μ(3)-oxido-1:2:4κO:O:O,2:3:4κO:O:O-tetra-tin(IV).

Authors:  Yip Foo Win; Siang Guan Teoh; Sie Tiong Ha; Reza Kia; Hoong-Kun Fun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-11-20

6.  Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.

Authors:  G He; J Kuang; Z Huang; J Koomen; R Kobayashi; A R Khokhar; Z H Siddik
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640

7.  Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Timothy C Johnstone; Hyunsuk Yoo; Wei Lin; Jamar G Brooks; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2014-06-06       Impact factor: 15.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.